Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models.
Adrenal cortical carcinomas (ACC) are rare but aggressive tumours associated with poor prognosis. The two most frequent alterations in ACC in patients are overexpression of the growth factor IGF2 and constitutive activation of Wnt/β-catenin signalling. Using a transgenic mouse model, we have previou...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22952916/pdf/?tool=EBI |
| _version_ | 1818400367945187328 |
|---|---|
| author | Coralie Drelon Annabel Berthon Bruno Ragazzon Frédérique Tissier Roberto Bandiera Isabelle Sahut-Barnola Cyrille de Joussineau Marie Batisse-Lignier Anne-Marie Lefrançois-Martinez Jérôme Bertherat Antoine Martinez Pierre Val |
| author_facet | Coralie Drelon Annabel Berthon Bruno Ragazzon Frédérique Tissier Roberto Bandiera Isabelle Sahut-Barnola Cyrille de Joussineau Marie Batisse-Lignier Anne-Marie Lefrançois-Martinez Jérôme Bertherat Antoine Martinez Pierre Val |
| author_sort | Coralie Drelon |
| collection | DOAJ |
| description | Adrenal cortical carcinomas (ACC) are rare but aggressive tumours associated with poor prognosis. The two most frequent alterations in ACC in patients are overexpression of the growth factor IGF2 and constitutive activation of Wnt/β-catenin signalling. Using a transgenic mouse model, we have previously shown that constitutive active β-catenin is a bona fide adrenal oncogene. However, although all these mice developed benign adrenal hyperplasia, malignant progression was infrequent, suggesting that secondary genetic events were required for aggressive tumour development. In the present paper, we have tested IGF2 oncogenic properties by developing two distinct transgenic mouse models of Igf2 overexpression in the adrenal cortex. Our analysis shows that despite overexpression levels ranging from 7 (basal) to 87 (ACTH-induced) fold, Igf2 has no tumour initiating potential in the adrenal cortex. However, it induces aberrant accumulation of Gli1 and Pod1-positive progenitor cells, in a hedgehog-independent manner. We have also tested the hypothesis that Igf2 may cooperate with Wnt signalling by mating Igf2 overexpressing lines with mice that express constitutive active β-catenin in the adrenal cortex. We show that the combination of both alterations has no effect on tumour phenotype at stages when β-catenin-induced tumours are benign. However, there is a mild promoting effect at later stages, characterised by increased Weiss score and proliferation. Formation of malignant tumours is nonetheless a rare event, even when Igf2 expression is further increased by ACTH treatment. Altogether these experiments suggest that the growth factor IGF2 is a mild contributor to malignant adrenocortical tumourigenesis. |
| first_indexed | 2024-12-14T07:35:27Z |
| format | Article |
| id | doaj.art-8a5aa1d0e2864f478757abec9540e2e9 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T07:35:27Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-8a5aa1d0e2864f478757abec9540e2e92022-12-21T23:11:13ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0178e4417110.1371/journal.pone.0044171Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models.Coralie DrelonAnnabel BerthonBruno RagazzonFrédérique TissierRoberto BandieraIsabelle Sahut-BarnolaCyrille de JoussineauMarie Batisse-LignierAnne-Marie Lefrançois-MartinezJérôme BertheratAntoine MartinezPierre ValAdrenal cortical carcinomas (ACC) are rare but aggressive tumours associated with poor prognosis. The two most frequent alterations in ACC in patients are overexpression of the growth factor IGF2 and constitutive activation of Wnt/β-catenin signalling. Using a transgenic mouse model, we have previously shown that constitutive active β-catenin is a bona fide adrenal oncogene. However, although all these mice developed benign adrenal hyperplasia, malignant progression was infrequent, suggesting that secondary genetic events were required for aggressive tumour development. In the present paper, we have tested IGF2 oncogenic properties by developing two distinct transgenic mouse models of Igf2 overexpression in the adrenal cortex. Our analysis shows that despite overexpression levels ranging from 7 (basal) to 87 (ACTH-induced) fold, Igf2 has no tumour initiating potential in the adrenal cortex. However, it induces aberrant accumulation of Gli1 and Pod1-positive progenitor cells, in a hedgehog-independent manner. We have also tested the hypothesis that Igf2 may cooperate with Wnt signalling by mating Igf2 overexpressing lines with mice that express constitutive active β-catenin in the adrenal cortex. We show that the combination of both alterations has no effect on tumour phenotype at stages when β-catenin-induced tumours are benign. However, there is a mild promoting effect at later stages, characterised by increased Weiss score and proliferation. Formation of malignant tumours is nonetheless a rare event, even when Igf2 expression is further increased by ACTH treatment. Altogether these experiments suggest that the growth factor IGF2 is a mild contributor to malignant adrenocortical tumourigenesis.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22952916/pdf/?tool=EBI |
| spellingShingle | Coralie Drelon Annabel Berthon Bruno Ragazzon Frédérique Tissier Roberto Bandiera Isabelle Sahut-Barnola Cyrille de Joussineau Marie Batisse-Lignier Anne-Marie Lefrançois-Martinez Jérôme Bertherat Antoine Martinez Pierre Val Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. PLoS ONE |
| title | Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. |
| title_full | Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. |
| title_fullStr | Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. |
| title_full_unstemmed | Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. |
| title_short | Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. |
| title_sort | analysis of the role of igf2 in adrenal tumour development in transgenic mouse models |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22952916/pdf/?tool=EBI |
| work_keys_str_mv | AT coraliedrelon analysisoftheroleofigf2inadrenaltumourdevelopmentintransgenicmousemodels AT annabelberthon analysisoftheroleofigf2inadrenaltumourdevelopmentintransgenicmousemodels AT brunoragazzon analysisoftheroleofigf2inadrenaltumourdevelopmentintransgenicmousemodels AT frederiquetissier analysisoftheroleofigf2inadrenaltumourdevelopmentintransgenicmousemodels AT robertobandiera analysisoftheroleofigf2inadrenaltumourdevelopmentintransgenicmousemodels AT isabellesahutbarnola analysisoftheroleofigf2inadrenaltumourdevelopmentintransgenicmousemodels AT cyrilledejoussineau analysisoftheroleofigf2inadrenaltumourdevelopmentintransgenicmousemodels AT mariebatisselignier analysisoftheroleofigf2inadrenaltumourdevelopmentintransgenicmousemodels AT annemarielefrancoismartinez analysisoftheroleofigf2inadrenaltumourdevelopmentintransgenicmousemodels AT jeromebertherat analysisoftheroleofigf2inadrenaltumourdevelopmentintransgenicmousemodels AT antoinemartinez analysisoftheroleofigf2inadrenaltumourdevelopmentintransgenicmousemodels AT pierreval analysisoftheroleofigf2inadrenaltumourdevelopmentintransgenicmousemodels |